Life's essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease

被引:0
|
作者
Zhang, Yingying [1 ]
Wang, Pingping [2 ]
Tu, Fan [1 ]
Kang, Hao [3 ]
Fu, Chengfeng [4 ]
机构
[1] Jiangnan Univ, Affiliated Wuxi Hosp 5, Med Lab Ctr, 1215 Guangrui Rd, Wuxi 214005, Jiangsu, Peoples R China
[2] Yangzhou Univ, Taizhou Peoples Hosp 2, Dept Clin Lab, Taizhou, Jiangsu, Peoples R China
[3] Jiangnan Univ, Affiliated Wuxi Hosp 5, Res Ctr Clin Med Sci, Wuxi, Jiangsu, Peoples R China
[4] Second Peoples Hosp Banan Dist, Resp & Crit Care Med, 18 Huaxi New Village,Huaxi St, Chongqing 400054, Peoples R China
关键词
MASLD; Life's essential 8; All-cause mortality; CVD mortality; National health and nutrition examination survey; AMERICAN HEART ASSOCIATIONS; CARDIOVASCULAR HEALTH; METAANALYSIS; OUTCOMES; METRICS; NHANES; RISK;
D O I
10.1186/s12889-024-20919-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to increased all-cause mortality due to metabolic dysfunctions like obesity, diabetes, and cardiovascular diseases. This study examines the association between Life's Essential 8 (LE8) scores and both all-cause and cardiovascular disease (CVD) mortality in MASLD participants. Methods Data from 5,916 MASLD participants in the NHANES (2005-2018) were analyzed. Associations between LE8 scores and all-cause and CVD mortality were assessed using Cox proportional hazards models, with follow-up until December 31, 2019. Dose-response relationships and survival differences were evaluated using Kaplan-Meier survival curves and Restricted Cubic Spline models. Results Over a median follow-up of 7.6 years, moderate and high LE8 scores were associated with 33% (HR: 0.67; 95% CI: 0.56-0.79) and 47% (HR: 0.53; 95% CI: 0.33-0.84) lower risk of all-cause mortality, respectively, compared to low scores. For CVD mortality, the adjusted HRs were 0.56 (95% CI: 0.41-0.78) and 0.35 (95% CI: 0.12-1.0). Higher LE8 scores were significantly associated with reduced cumulative incidence of all-cause and CVD mortality (log-rank P < 0.001). A 10-point increase in health behavior scores, particularly in diet, physical activity, and nicotine exposure, was linked to an 11% reduction in all-cause mortality risk and an 11% reduction in CVD mortality risk. Among health factors, only blood glucose showed a significant association with CVD mortality. Conclusion Higher LE8 scores in MASLD patients are associated with lower mortality risk, suggesting the potential value of promoting cardiovascular health in this population. Further research is needed to confirm these associations.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Beyoglu, Diren
    Popov, Yury V.
    Idle, Jeffrey R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [32] Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
    Gambardella, Maria Luisa
    Abenavoli, Ludovico
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)
  • [33] flammation inhibitor for metabolic dysfunction-associated steatotic liver disease therapy
    Kang, Wang
    Zhang, Pengfei
    Sun, Huiyong
    Cui, Shuang
    Ao, Lanjia
    Cui, Ming
    Xu, Xiaowei
    Wang, Lin
    Xu, Yuanyuan
    Wang, Guangji
    Hong, Wang
    Haiping, Hao
    CHINESE JOURNAL OF NATURAL MEDICINES, 2024, 22 (11) : 965 - 976
  • [34] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [35] Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers
    Mantovani, Alessandro
    Lonardo, Amedeo
    Stefan, Norbert
    Targher, Giovanni
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 160
  • [36] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025, : 94 - 103
  • [37] Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease
    Tincopa, Monica A.
    Diaz, Luis Antonio
    Huang, Daniel Q.
    Arab, Juan Pablo
    Arrese, Marco
    Gadano, Adrian
    Oliveira, Claudia P.
    Bettencourt, Richele
    Madamba, Egbert
    Kim, Susy
    Siddiqi, Harris
    Barreyro, Fernando Javier
    Marciano, Sebastian
    Martinez Morales, Jorge
    Villela-Nogueira, Cristiane
    Leite, Nathalie
    Couto, Claudia Alves
    Theodoro, Rafael
    Joyner de Sousa Dias Monteiro, Misia
    Pessoa, Mario G.
    Alvares-da-Silva, Mario Reis
    Higuera de la Tijera, Fatima
    Sabate, Constanza D.
    Mendizabal, Manuel
    Richards, Lisa
    Sirlin, Claude B.
    Loomba, Rohit
    HEPATOLOGY, 2024,
  • [38] The liver-brain axis in metabolic dysfunction-associated steatotic liver disease
    Mikkelsen, Anne Catrine Daugaard
    Kjaergaard, Kristoffer
    Schapira, Anthony H. V.
    Mookerjee, Rajeshwar P.
    Thomsen, Karen Louise
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 248 - 258
  • [39] Pharmacological management of pediatric metabolic dysfunction-associated steatotic liver disease
    Abou Jaoudeh, Rasha Abi Radi
    Hartmann, Phillipp
    Olson, Ole
    Gupta, Olga
    Kumar, Seema
    Ibrahim, Samar H.
    Fawaz, Rima
    Aqul, Amal
    Hassan, Sara
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2025, 80 (01) : 14 - 24
  • [40] Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Maher, Salim
    Rajapakse, Jayashi
    El-Omar, Emad
    Zekry, Amany
    SEMINARS IN LIVER DISEASE, 2024, 44 (04) : 457 - 473